- Home
- PGY vs HCM Comparison
PGY vs HCM Comparison
Compare PGY & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- HCM
- Stock Information
- Founded
- PGY 2016
- HCM 2000
- Country
- PGY United States
- HCM Hong Kong
- Employees
- PGY N/A
- HCM N/A
- Industry
- PGY Finance: Consumer Services
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- PGY Finance
- HCM Health Care
- Exchange
- PGY Nasdaq
- HCM Nasdaq
- Market Cap
- PGY 2.4B
- HCM 2.5B
- IPO Year
- PGY N/A
- HCM N/A
- Fundamental
- Price
- PGY $33.30
- HCM $16.45
- Analyst Decision
- PGY Strong Buy
- HCM Strong Buy
- Analyst Count
- PGY 9
- HCM 1
- Target Price
- PGY $34.44
- HCM $28.00
- AVG Volume (30 Days)
- PGY 4.0M
- HCM 45.4K
- Earning Date
- PGY 08-07-2025
- HCM 08-07-2025
- Dividend Yield
- PGY N/A
- HCM N/A
- EPS Growth
- PGY N/A
- HCM N/A
- EPS
- PGY N/A
- HCM 0.53
- Revenue
- PGY $1,153,015,000.00
- HCM $602,197,000.00
- Revenue This Year
- PGY $23.03
- HCM $15.00
- Revenue Next Year
- PGY $15.51
- HCM $19.91
- P/E Ratio
- PGY N/A
- HCM $5.83
- Revenue Growth
- PGY 24.59
- HCM N/A
- 52 Week Low
- PGY $8.20
- HCM $11.51
- 52 Week High
- PGY $41.48
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- PGY 63.07
- HCM 48.78
- Support Level
- PGY $31.24
- HCM $15.80
- Resistance Level
- PGY $34.36
- HCM $16.17
- Average True Range (ATR)
- PGY 3.29
- HCM 0.50
- MACD
- PGY -0.11
- HCM -0.23
- Stochastic Oscillator
- PGY 40.85
- HCM 37.24
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.